Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.3401
Nov 05 • 3:59 PM ET Dollar change-0.0266 Percentage change(-7.25%)
Aftermarket Close
0.3401
Aftermarket • 4:15 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
-
Market Cap
13.62M
Enterprise Value
14.00M
Income
-7.62M
Sales
3.80M
Book/sh
-0.07
Cash/sh
0.12
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
5
IPO
Nov 05, 2004
P/E
-
Forward P/E
11.34
PEG
0.17
P/S
3.59
P/B
-
P/C
2.92
P/FCF
-
EV/EBITDA
-
EV/Sales
3.69
Quick Ratio
1.65
Current Ratio
1.65
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.21
EPS next Y
0.03
EPS next Q
-0.04
EPS this Y
39.13%
EPS next Y
121.43%
EPS next 5Y
64.84%
EPS past 3/5Y
13.04% 7.84%
Sales past 3/5Y
1.79% 14.04%
EPS Y/Y TTM
-14.12%
Sales Y/Y TTM
-8.05%
EPS Q/Q
2.18%
Sales Q/Q
-0.57%
Insider Own
23.02%
Insider Trans
-2.83%
Inst Own
20.15%
Inst Trans
-2.94%
ROA
-103.88%
ROE
-2826.92%
ROIC
-287.21%
Gross Margin
16.24%
Oper. Margin
-194.50%
Profit Margin
-200.46%
SMA20
-13.74%
SMA50
-22.73%
SMA200
-54.69%
Trades
Shs Outstand
36.44M
Shs Float
30.84M
52W High
1.60 -78.74%
52W Low
0.34 0.00%
Volatility
7.78% 9.50%
ATR (14)
0.04
RSI (14)
31.76
Beta
1.08
Rel Volume
0.50
Avg Volume
163.23K
Volume
81,585
Perf Week
-5.79%
Perf Month
-25.50%
Perf Quarter
-65.99%
Perf Half Y
-54.35%
Perf YTD
-63.82%
Perf Year
-67.30%
Perf 3Y
-79.76%
Perf 5Y
-91.73%
Perf 10Y
-79.39%
Prev Close
0.37
Price
0.34
Change %
-7.25%
Consensus
Strong Buy
Avg. Price Target
$5.50
Implied Upside
+1,517.2%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 23, 2025Resumed
HH.C. Wainwright
Buy$3+782.1%
Sep 08, 2025Initiated
CCraig Hallum
Buy
Jul 18, 2022Downgrade
DDawson James
Buy → Neutral
Dec 17, 2021Initiated
HH.C. Wainwright
Buy$7+1,958.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Francisco Trust under agreemen10% OwnerJul 23 '26Sale1.3054,76071,3033,282,888Jul 24 05:11 PM
Francisco Trust under agreemen10% OwnerJul 22 '26Sale1.3338,01650,4813,337,648Jul 24 05:11 PM
Francisco Trust under agreemen10% OwnerJul 24 '26Sale1.212,6163,1733,280,272Jul 24 05:11 PM
Francisco Trust under agreemenGreater than 10% holderJul 21 '26Proposed Sale1.48364,387539,296Jul 21 05:52 PM
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
FounderMr. Mark A. Emalfarb
President & COOMr. Joseph P. Hazelton
M.B.A.Ms. Ping Wang Rawson CPA
Secretary of the BoardMs. Ana Gomez Rodriguez